Anti-Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic, etiology of inflammatory synovitis-based systemic disease. It is characterized by hand, small joints of the joints, symmetry, invasive joint inflammation, often associated with external organ involvement and serum rheumatoid factor positive, can lead to joint deformity and loss of function. According to statistics, the incidence of rheumatoid arthritis in women is 2 to 3 times that of men.It can occur at any age, high incidence of age 40 to 60 years old. People who has rheumatoid arthritis in the late, severe or long-term bedridden patients, due to combined infection, gastrointestinal bleeding, heart, lung or kidney disease can be crisis to life. The main purpose of treatment for Rheumatoid arthritis is to reduce the inflammation of the joints, inhibit the development of lesions and irreversible bone destruction, as far as possible to protect the function of joints and muscles, and ultimately achieve complete disease remission or low disease activity target. Treatment principles include 1. Patient education, 2. General treatment 3. Drug treatment 4. Immune purification 5. Functional exercise 6. Surgical treatment. Anti-Rheumatoid arthritis drug treatment mainly includes non-steroidal anti-inflammatory drugs, slow-acting anti-rheumatic drugs, immunosuppressive agents, immune and biological agents and botanicals. Over the past decade, the treatment of extra-articular lesions and the emergence of new therapies, so that the efficacy of rheumatoid arthritis has been significantly improved. Most patients with rheumatoid arthritis can get a good control or even complete remission.


CAS 90536-66-6/[Etoricoxib Intermediates]4-Methylsulphonylphenylacetic acid
CAS 90536-66-6/[Etoricoxib Intermediates]4-Methylsulphonylphenylacetic acid
CAS 221615-72-1,[Etoricoxib Intermediates]1-(6-Methylpyridin-3-yl)-2-[4-(methylthio)phenyl]ethanone
CAS 221615-72-1,[Etoricoxib Intermediates]1-(6-Methylpyridin-3-yl)-2-[4-(methylthio)phenyl]ethanone
CAS 221615-75-4 Etoricoxib Intermediates 1-(6-methyl-3-pyridyl)-2-(4-(methylsulfonyl)-phenyl)ethanone
CAS 221615-75-4 Etoricoxib Intermediates 1-(6-methyl-3-pyridyl)-2-(4-(methylsulfonyl)-phenyl)ethanone
149436-41-9, High Quality Iguratimod Intermediate
149436-41-9, High Quality Iguratimod Intermediate
149457-03-4, Intermediate of Iguratimod
149457-03-4, Intermediate of Iguratimod
CAS 149457-03-4,MethanesulfonaMide,N-[4-[2-(forMylaMino)acetyl]-5-hydroxy-2-phenoxyphenyl] For Iguratimod
CAS 149457-03-4,MethanesulfonaMide,N-[4-[2-(forMylaMino)acetyl]-5-hydroxy-2-phenoxyphenyl] For Iguratimod
CAS 149436-41-9, Iguratimod Intermediate
CAS 149436-41-9, Iguratimod Intermediate
MFCD06658411, 4-Chloro-5H-pyrrolo[3,2-d]pyrimidine CAS 84905-80-6
MFCD06658411, 4-Chloro-5H-pyrrolo[3,2-d]pyrimidine CAS 84905-80-6
4-Pyrazoleboronic Acid Pinacol Ester For Baricitinib  CAS 269410-08-4
4-Pyrazoleboronic Acid Pinacol Ester For Baricitinib CAS 269410-08-4
Baricitinib (LY3009104, INCB028050) Intermediates CAS 1153949-11-1
Baricitinib (LY3009104, INCB028050) Intermediates CAS 1153949-11-1
4-Chloro-7-((2-(Trimethylsilyl)ethoxy)Methyl)-7H-Pyrrolo[2,3-d]pyrimidine CAS 941685-26-3
4-Chloro-7-((2-(Trimethylsilyl)ethoxy)Methyl)-7H-Pyrrolo[2,3-d]pyrimidine CAS 941685-26-3
High Quality (4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl Pivalate CAS 1146629-75-5
High Quality (4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl Pivalate CAS 1146629-75-5
Synthesis LY3009104/ INCB028050 Baricitinib Intermediate 1146629-77-7
Synthesis LY3009104/ INCB028050 Baricitinib Intermediate 1146629-77-7
A Potent JAK1 and JAK2 Inhibitor Baricitinib CAS 1187594-09-7
A Potent JAK1 and JAK2 Inhibitor Baricitinib CAS 1187594-09-7
Customization 2-(1-(Ethylsulfonyl)azetidin-3-ylidene)acetonitrile CAS 1187595-85-2
Customization 2-(1-(Ethylsulfonyl)azetidin-3-ylidene)acetonitrile CAS 1187595-85-2
Synthesis JAK1 and JAK2 Inhibitor Baricitinib Intermediate CAS 1029716-44-6
Synthesis JAK1 and JAK2 Inhibitor Baricitinib Intermediate CAS 1029716-44-6
Baricitinib Intermediate 6-Chloro-7-deazapurine  CAS 3680-69-1
Baricitinib Intermediate 6-Chloro-7-deazapurine CAS 3680-69-1
Intermediate of Baricitinib CAS 941685-27-4
Intermediate of Baricitinib CAS 941685-27-4
Intermediates Baricitinib CAS Number 941685-26-3
Intermediates Baricitinib CAS Number 941685-26-3
CAS 1187595-85-2, Intermediate of Baricitinib
CAS 1187595-85-2, Intermediate of Baricitinib
Lesinurad Impurity CAS Number 878671-99-9
Lesinurad Impurity CAS Number 878671-99-9
Lesinurad Int CAS 1533519-85-5
Lesinurad Int CAS 1533519-85-5
Lesinurad Impurity CAS 1533519-84-4
Lesinurad Impurity CAS 1533519-84-4
LESINURAD Intermediate CAS 1533519-86-6
LESINURAD Intermediate CAS 1533519-86-6

© 2019 CHINA WAY. All Rights Reserved.  Taizhou Volsen Chemical Co., Ltd.,  Inc.   All rights reserved. site map.  sitemap.html